Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740129 | 0.86 | KDM4E (0.49) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL5045034 | 0.86 | KDM4E (0.49) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL2740223 | 0.84 | MAPT (0.59) | SIRT1MAPTKDM4EALDH1A1GAA | |
| SCHEMBL2624604 | 0.84 | GLO1 (0.56) | SIRT1MAPTKDM4EALDH1A1GAA | |
| SCHEMBL2624486 | 0.83 | SIRT1 (0.49) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL2740131 | 0.82 | KDM4E (0.50) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL2740130 | 0.79 | SIRT1 (0.65) | SIRT1MAPTNPSR1TDP1TP53 | |
| SCHEMBL2740128 | 0.79 | SLC40A1 (0.49) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL5020212 | 0.78 | SLC40A1 (0.56) | SIRT1MAPTNPSR1TDP1KDM4E | |
| SCHEMBL2740226 | 0.77 | CYP2C9 (0.60) | MAPTNPSR1KDM4ETP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304206-B2 | Mass spectrometry assays for identifying compounds that activate deacetylases | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090221020-A1 | Mass Spectrometry Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885MAPT 625/4885NPSR1 3305/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | SIRT1 271/4885MAPT 1946/4885NPSR1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.